Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000349:Africa; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D004341:Drug Evaluation; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D007538:Isoniazid / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D011718:Pyrazinamide / Q000008:administration & dosage* / Q000627:therapeutic use; D012008:Recurrence; D012293:Rifampin / Q000008:administration & dosage* / Q000627:therapeutic use; D013183:Sputum / Q000382:microbiology; D013307:Streptomycin / Q000008:administration & dosage* / Q000627:therapeutic use; D013828:Thioacetazone / Q000008:administration & dosage* / Q000627:therapeutic use; D013997:Time Factors; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000382:microbiology
D004338:Drug Combinations; D011718:Pyrazinamide; D013828:Thioacetazone; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin